← Eichor
Condition: Rai Refractory Thyroid Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Rai Refractory Thyroid Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
Phase N/A · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT05733013Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT03099356I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer
Phase N/A · 1 location(s) · Miami Cancer Research Center, Inc. · NCT06443866Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Phase 2 · 6 location(s) · Massachusetts General Hospital · NCT05668962Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Phase 3 · 301 location(s) · ECOG-ACRIN Cancer Research Group · NCT06475989A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06007924
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.